In adult ASA I‑III patients undergoing elective surgery, what intra‑operative hemodynamic parameter was used as the primary objective?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mean Arterial Pressure (MAP) Was the Primary Hemodynamic Objective

The most recent high-quality evidence demonstrates that mean arterial pressure (MAP) served as the primary intraoperative hemodynamic parameter in adult ASA I-III patients undergoing elective surgery, with specific target thresholds being the focus of optimization strategies.

MAP as the Central Hemodynamic Target

The contemporary evidence consistently identifies MAP as the primary objective for intraoperative hemodynamic management:

  • The HISTAP trial 1 directly compared MAP targets of ≥80 mmHg versus ≥65 mmHg in hypertensive high-risk patients undergoing major abdominal surgery, demonstrating that the higher MAP target reduced major organ dysfunction (38.1% vs 48.9%, P=0.006), primarily through decreased acute kidney injury.

  • The standard threshold of MAP <65 mmHg defines intraoperative hypotension (IOH) across multiple recent studies 2, 3, establishing this as the critical hemodynamic parameter being monitored and optimized.

Alternative Hemodynamic Parameters Studied

While MAP remains primary, other parameters have been investigated as secondary optimization targets:

Cardiac Index-Guided Therapy: The PELICAN trial 4 evaluated individualized cardiac index-guided hemodynamic therapy targeting each patient's preoperative resting cardiac index versus routine hemodynamic therapy in 1,095 high-risk patients. This approach did not improve outcomes (primary composite outcome: 44.3% vs 46.9%, P=0.38), suggesting cardiac index optimization alone is insufficient when used as the primary target.

Flow-Derived vs Predictive Monitoring: Advanced monitoring platforms measure MAP differently but still use it as the primary parameter. The Hypotension Prediction Index (HPI) system was associated with less cumulative IOH duration compared to Vigileo/FloTrac monitoring 2, but both systems fundamentally target MAP maintenance.

Clinical Implications for Hemodynamic Management

For hypertensive patients (age ≥60 with chronic hypertension): Target intraoperative MAP ≥80 mmHg rather than the standard ≥65 mmHg threshold 1. This higher target specifically reduces acute kidney injury risk (23.5% vs 33.7%, P=0.005).

For general high-risk populations: Maintain MAP ≥65 mmHg as the minimum threshold, as distinct hemodynamic phenotypes show graded increases in complications when this threshold is violated 3. Patients with sustained hypotension (phenotype 4) experienced 41.4% AKI rates versus 4.9% in hemodynamically stable patients.

Common Pitfalls

  • Avoid relying solely on cardiac index optimization without concurrent MAP management, as the PELICAN trial 4 demonstrated no benefit from this approach alone
  • Recognize patient-specific factors: The one-size-fits-all MAP ≥65 mmHg may be inadequate for chronically hypertensive patients who require higher perfusion pressures 1
  • Duration matters: Both cumulative hypotension duration and frequency of episodes correlate with outcomes 2, not just isolated measurements

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.